Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil
Open Access
- 30 August 2019
- journal article
- research article
- Published by Elsevier BV in Annals of Hepatology
- Vol. 18 (6), 849-854
- https://doi.org/10.1016/j.aohep.2019.08.001
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET StudyClinical Infectious Diseases, 2016
- Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence – The ANRS CUPILT studyJournal of Hepatology, 2016
- Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1The Esophagus, 2016
- Liver Transplantation in BrazilLiver Transplantation, 2016
- Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal functionLiver International, 2016
- Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)Hepatology, 2016
- Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionGastroenterology, 2016
- Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohortZeitschrift für Gastroenterologie, 2015
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalenceHepatology, 2013
- Trends and projections of hepatitis C virus epidemiology in Latin AmericaLiver International, 2011